Change in fatigue and serum iron status 12 weeks after treatment initiation with intravenous iron or intravenous placebo
| . | Iron group . | Placebo group . | P . |
|---|---|---|---|
| Total study population (n = 90) | |||
| Change of fatigue (BFI), median | −1.3 (−2.4, −0.5) | −0.9 (−2.2, 0.0) | ns |
| Fatigue improved (SPI), n (%) | 27/43 (63%) | 16/47 (34%) | .006 |
| Change of ferritin concentration, ng/mL | 81 (49, 100) | −1 (−7, 4) | < .001 |
| Change of transferrin saturation, % | 7 (0, 17) | 1 (5, 6) | .006 |
| Population with baseline ferritin ≤ 15 ng/mL (n = 34) | |||
| Change of fatigue (BFI), median | −2.3 (−3.2, 0.9) | −0.7 (−1.3, 0.1) | .03 |
| Fatigue improved (SPI), n (%) | 14/17 (82%) | 6/17 (35%) | .005 |
| . | Iron group . | Placebo group . | P . |
|---|---|---|---|
| Total study population (n = 90) | |||
| Change of fatigue (BFI), median | −1.3 (−2.4, −0.5) | −0.9 (−2.2, 0.0) | ns |
| Fatigue improved (SPI), n (%) | 27/43 (63%) | 16/47 (34%) | .006 |
| Change of ferritin concentration, ng/mL | 81 (49, 100) | −1 (−7, 4) | < .001 |
| Change of transferrin saturation, % | 7 (0, 17) | 1 (5, 6) | .006 |
| Population with baseline ferritin ≤ 15 ng/mL (n = 34) | |||
| Change of fatigue (BFI), median | −2.3 (−3.2, 0.9) | −0.7 (−1.3, 0.1) | .03 |
| Fatigue improved (SPI), n (%) | 14/17 (82%) | 6/17 (35%) | .005 |
Results are presented as median values (quartiles Q1, Q3) or number of patients (%). P values were calculated with the Mann Whitney U test or the χ2 test.
ns indicates not significant and no trend (P > .10).